A while back, I questioned Mr. Marckz on the timeline for their estimate. His response at the time:
Our valuations are based on a 6 - 12 months timeframe. Our revenue estimates are based on the current customer base, an expectation that the customer base continues to grow, entry into countries where CTSO does not currently have a presence and other catalysts, such as Fresenius coming online. Relative to potential stocking orders - those may or may not be signficant - it's very much dependent on Fresenius and there's no way to be able to judge the size of a potential inventory stocking order. Fresenius, once they begin sell-through sales, could be a very significant contributor. But it's important to understand that with a product like CytoSorb, potential sales are not driven by distribution-reach as much as they are by clinical outcomes. My thesis relies on continued potisive clinical data, particularly published data from larger studies as the main catalyst to revenue growth. And studies, data and publications take time which is relfected in my growth rates. Regarding the Middle East, that has not come online as soon as maybe expected. CTSO indicated on the call that that is still on the front burner however.
News 
Market Data 
Discover 
